Hassan Albadawi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Hassan Albadawi has a total of 88 co-authors. Here are the top co-authors by number of shared publications:
- Rahmi Oklu
The Laboratory for Patient‐Inspired Engineering Mayo Clinic 13400 East Shea Blvd. Scottsdale AZ 85259 USA
11 shared publications Michael T. Watkins
From the Department of Surgery, Division of Vascular and Endovascular Surgery (H.A., J.D.M., R.P.C., M.T.W.), and Center for System Biology and Institute for Innovation in Imaging, Department of Radiology (J.W.C., Y.W., G.W., B.P.), Massachusetts General Hospital, Harvard Medical School, 70 Blossom St, Edwards 301, Boston, MA 02114; and Department of Radiology, Division of Vascular and Interventional Radiology, Mayo Clinic, Scottsdale, Ariz (R.O.).
7 shared publicationsHyung-Jin Yoo
Division of Vascular and Endovascular Surgery, Department of Surgery, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts
5 shared publicationsMichael A. Peck
Division of Vascular and Endovascular Surgery, Department of Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
3 shared publications- Michael T. Watkins
Division of Vascular and Endovascular Surgery, Department of Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts
3 shared publications Robert S. Crawford
3 shared publications
Latest Publications
- 3 July 2024
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 16 (754) , eadn7982
Prostate tissue ablation and drug delivery by an image-guided injectable ionic liquid in ex vivo and in vivo models
Benign prostatic hyperplasia and prostate cancer are often associated with lower urinary tract symptoms, which can severely affect patient quality of life. To address this challenge, we developed and optimized an injectable compound, prostate ablation and drug delivery agent (PADA), for percutaneous prostate tissue ablation and concurrently delivered therapeutic agents. PADA is an ionic liquid composed of choline and geranic acid mixed with anticancer therapeutics and a contrast agent. The PADA formulation was optimized for mechanical properties compatible with hand injection, diffusion capability, cytotoxicity against prostate cells, and visibility of an x-ray contrast agent. PADA also exhibited antibacterial properties against highly resistant clinically isolated bacteria in vitro. Ultrasound-guided injection, dispersion of PADA in the tissue, and tissue ablation were tested ex vivo in healthy porcine, canine, and human prostates and in freshly resected human tumors. In vivo testing was conducted in a murine subcutaneous tumor model and in the canine prostate. In all models, PADA decreased the number of viable cells in the region of dispersion and supported the delivery of nivolumab throughout a portion of the tissue. In canine survival experiments, there were no adverse events and no impact on urination. The injection approach was easy to perform under ultrasound guidance and produced a localized effect with a favorable safety profile. These findings suggest that PADA is a promising therapeutic prostate ablation strategy to treat lower urinary tract symptoms.
- 3 July 2024
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 16 (754) , eadn7982
Prostate tissue ablation and drug delivery by an image-guided injectable ionic liquid in ex vivo and in vivo models
Benign prostatic hyperplasia and prostate cancer are often associated with lower urinary tract symptoms, which can severely affect patient quality of life. To address this challenge, we developed and optimized an injectable compound, prostate ablation and drug delivery agent (PADA), for percutaneous prostate tissue ablation and concurrently delivered therapeutic agents. PADA is an ionic liquid composed of choline and geranic acid mixed with anticancer therapeutics and a contrast agent. The PADA formulation was optimized for mechanical properties compatible with hand injection, diffusion capability, cytotoxicity against prostate cells, and visibility of an x-ray contrast agent. PADA also exhibited antibacterial properties against highly resistant clinically isolated bacteria in vitro. Ultrasound-guided injection, dispersion of PADA in the tissue, and tissue ablation were tested ex vivo in healthy porcine, canine, and human prostates and in freshly resected human tumors. In vivo testing was conducted in a murine subcutaneous tumor model and in the canine prostate. In all models, PADA decreased the number of viable cells in the region of dispersion and supported the delivery of nivolumab throughout a portion of the tissue. In canine survival experiments, there were no adverse events and no impact on urination. The injection approach was easy to perform under ultrasound guidance and produced a localized effect with a favorable safety profile. These findings suggest that PADA is a promising therapeutic prostate ablation strategy to treat lower urinary tract symptoms.
- 23 January 2024
- Published by Elsevier in Journal of Vascular and Interventional Radiology
- Vol. 35 (2) , 164-172
Advances and Challenges in Interventional Immuno-Oncology Locoregional Therapies
- 23 January 2024
- Published by Elsevier in Journal of Vascular and Interventional Radiology
- Vol. 35 (2) , 164-172
Advances and Challenges in Interventional Immuno-Oncology Locoregional Therapies
- 9 March 2022
- Published by SPIE-Intl Soc Optical Eng
- p. 18
Aging of deep venous thrombosis using polarization sensitive optical coherence tomography
SPIE Digital Library Proceedings
- 9 March 2022
- Published by SPIE-Intl Soc Optical Eng
- p. 18
Aging of deep venous thrombosis using polarization sensitive optical coherence tomography
SPIE Digital Library Proceedings
- 10 February 2021
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 13 (580)
Percutaneous liquid ablation agent for tumor treatment and drug delivery
An ionic liquid formulation ablates tumors, uniformly distributes drugs in the ablation zone, and has synergistic effects with chemotherapy.
- 10 February 2021
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 13 (580)
Percutaneous liquid ablation agent for tumor treatment and drug delivery
An ionic liquid formulation ablates tumors, uniformly distributes drugs in the ablation zone, and has synergistic effects with chemotherapy.
- 12 August 2019
- Published by Springer Nature in Abdominal Radiology
- Vol. 44 (10) , 3453-3462
Current concepts in portal vein thrombosis: etiology, clinical presentation and management
The aim of this article is to focus on etiology, risk factors, clinical presentation and classification systems of acute and chronic PVT as well as focusing on current diagnostic and therapeutic options for the management of acute and chronic PVT. PVT represents a serious clinical concern in cirrhotic patients and in those with specific local or systemic risk factors. The rate and extent of thrombus formation can significantly impact patient presentation and the resulting clinical outcomes. The presentation of acute PVT can range from abdominal pain to intestinal ischemia/infarction and even death, while chronic PVT can remain clinically silent. A number of imaging modalities including US, CT and MRI can be used to confirm the diagnosis. In addition to addressing underlying risk factors, AC therapy forms a cornerstone of treatment and has demonstrated efficacy in both acute and chronic settings. Proper caution should be used when initiating AC therapy in cirrhotic patients given their underlying coagulopathic status with attention now being paid to NOACs and LMWH. For patients with bowel ischemia, extensive thrombosis, contraindications or poor response to AC, or for those with co-morbidities that preclude AC, minimally invasive endovascular techniques offer alternative treatment options. Familiarity with the etiology, clinical presentation and classification of PVT optimize early detection and incorporate effective therapeutic options, the management of these complex patients should be undertaken by a multidisciplinary team. Minimally invasive catheter-based therapies and endovascular portosystemic shunt creation demonstrated efficacy in the treatment of AC-resistant patients and for patients with extensive or complicated disease.
- 12 August 2019
- Published by Springer Nature in Abdominal Radiology
- Vol. 44 (10) , 3453-3462
Current concepts in portal vein thrombosis: etiology, clinical presentation and management
The aim of this article is to focus on etiology, risk factors, clinical presentation and classification systems of acute and chronic PVT as well as focusing on current diagnostic and therapeutic options for the management of acute and chronic PVT. PVT represents a serious clinical concern in cirrhotic patients and in those with specific local or systemic risk factors. The rate and extent of thrombus formation can significantly impact patient presentation and the resulting clinical outcomes. The presentation of acute PVT can range from abdominal pain to intestinal ischemia/infarction and even death, while chronic PVT can remain clinically silent. A number of imaging modalities including US, CT and MRI can be used to confirm the diagnosis. In addition to addressing underlying risk factors, AC therapy forms a cornerstone of treatment and has demonstrated efficacy in both acute and chronic settings. Proper caution should be used when initiating AC therapy in cirrhotic patients given their underlying coagulopathic status with attention now being paid to NOACs and LMWH. For patients with bowel ischemia, extensive thrombosis, contraindications or poor response to AC, or for those with co-morbidities that preclude AC, minimally invasive endovascular techniques offer alternative treatment options. Familiarity with the etiology, clinical presentation and classification of PVT optimize early detection and incorporate effective therapeutic options, the management of these complex patients should be undertaken by a multidisciplinary team. Minimally invasive catheter-based therapies and endovascular portosystemic shunt creation demonstrated efficacy in the treatment of AC-resistant patients and for patients with extensive or complicated disease.
- Open Access
- 1 November 2017
- Published by Taylor & Francis in Oncolytic Virotherapy
- Vol. ume 6, 39-49
Oncolytic virus delivery: from nano-pharmacodynamics to enhanced oncolytic effect
With the advancement of a growing number of oncolytic viruses (OVs) to clinical development, drug delivery is becoming an important barrier to overcome for optimal therapeutic benefits. Host immunity, tumor microenvironment and abnormal vascularity contribute to inefficient vector delivery. A number of novel approaches for enhanced OV delivery are under evaluation, including use of nanoparticles, immunomodulatory agents and complex viral–particle ligands along with manipulations of the tumor microenvironment. This field of OV delivery has quickly evolved to bioengineering of complex nanoparticles that could be deposited within the tumor using minimal invasive image-guided delivery. Some of the strategies include ultrasound (US)-mediated cavitation-enhanced extravasation, magnetic viral complexes delivery, image-guided infusions with focused US and targeting photodynamic virotherapy. In addition, strategies that modulate tumor microenvironment to decrease extracellular matrix deposition and increase viral propagation are being used to improve tumor penetration by OVs. Some involve modification of the viral genome to enhance their tumoral penetration potential. Here, we highlight the barriers to oncolytic viral delivery, and discuss the challenges to improving it and the perspectives of establishing new modes of active delivery to achieve enhanced oncolytic effects.
- 1 November 2017
- Published by Taylor & Francis in Oncolytic Virotherapy
- Vol. ume 6, 39-49
Open AccessOncolytic virus delivery: from nano-pharmacodynamics to enhanced oncolytic effect
With the advancement of a growing number of oncolytic viruses (OVs) to clinical development, drug delivery is becoming an important barrier to overcome for optimal therapeutic benefits. Host immunity, tumor microenvironment and abnormal vascularity contribute to inefficient vector delivery. A number of novel approaches for enhanced OV delivery are under evaluation, including use of nanoparticles, immunomodulatory agents and complex viral–particle ligands along with manipulations of the tumor microenvironment. This field of OV delivery has quickly evolved to bioengineering of complex nanoparticles that could be deposited within the tumor using minimal invasive image-guided delivery. Some of the strategies include ultrasound (US)-mediated cavitation-enhanced extravasation, magnetic viral complexes delivery, image-guided infusions with focused US and targeting photodynamic virotherapy. In addition, strategies that modulate tumor microenvironment to decrease extracellular matrix deposition and increase viral propagation are being used to improve tumor penetration by OVs. Some involve modification of the viral genome to enhance their tumoral penetration potential. Here, we highlight the barriers to oncolytic viral delivery, and discuss the challenges to improving it and the perspectives of establishing new modes of active delivery to achieve enhanced oncolytic effects.
- 1 January 2017
- Published by Radiological Society of North America (RSNA) in Radiology
- Vol. 282 (1) , 202-211
Spinal Cord Inflammation: Molecular Imaging after Thoracic Aortic Ischemia Reperfusion Injury
The proinflammatory enzyme myeloperoxidase, which is secreted by activated myeloid cells, could represent a key imaging biomarker for tracking early inflammatory changes noninvasively in the spinal... PurposeTo evaluate whether noninvasive molecular imaging technologies targeting myeloperoxidase (MPO) can reveal early inflammation associated with spinal cord injury after thoracic aortic ischemia...
- 1 January 2017
- Published by Radiological Society of North America (RSNA) in Radiology
- Vol. 282 (1) , 202-211
Spinal Cord Inflammation: Molecular Imaging after Thoracic Aortic Ischemia Reperfusion Injury
The proinflammatory enzyme myeloperoxidase, which is secreted by activated myeloid cells, could represent a key imaging biomarker for tracking early inflammatory changes noninvasively in the spinal... PurposeTo evaluate whether noninvasive molecular imaging technologies targeting myeloperoxidase (MPO) can reveal early inflammation associated with spinal cord injury after thoracic aortic ischemia...
- 1 August 2016
- Published by Elsevier in Journal of Vascular Surgery
- Vol. 64 (2) , 484-493
Effect of DNase I treatment and neutrophil depletion on acute limb ischemia-reperfusion injury in mice
- 1 August 2016
- Published by Elsevier in Journal of Vascular Surgery
- Vol. 64 (2) , 484-493
Effect of DNase I treatment and neutrophil depletion on acute limb ischemia-reperfusion injury in mice
- Open Access
- 8 June 2016
- Published by Elsevier in Journal of Surgical Research
- Vol. 205 (1) , 49-58
Revascularization and muscle adaptation to limb demand ischemia in diet-induced obese mice
- 8 June 2016
- Published by Elsevier in Journal of Surgical Research
- Vol. 205 (1) , 49-58
Open AccessRevascularization and muscle adaptation to limb demand ischemia in diet-induced obese mice
- 9 April 2015
- Published by Elsevier in Journal of Surgical Research
- Vol. 198 (2) , 515-524
Effect of limb demand ischemia on autophagy and morphology in mice
- 9 April 2015
- Published by Elsevier in Journal of Surgical Research
- Vol. 198 (2) , 515-524
Effect of limb demand ischemia on autophagy and morphology in mice